Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 18,278 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Controlled Group Clear all

Conditions: Fuchs' Endothelial Dystrophy, Corneal Edema
Interventions: Endothelial keratoplasty, PRGF; Procedure · Biological
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Miami, Florida • Indianapolis, Indiana

Conditions: Coronary Artery Disease (CAD), Coronary Atherosclerosis
Interventions: Placebo, Aliskiren; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 35 Years and older
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 54
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 48 more

Conditions: Type 1 Diabetes
Interventions: SPACE for T1D, Enhanced usual care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 5 Years to 12 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Skin Neoplasms
Interventions: Tranexamic acid injection, Lidocaine Epinephrine; Drug
Lead sponsor: Riley McLean; Other
Eligibility: 18 Years to 99 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Epilepsy
Interventions: Lacosamide, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 4 Years to 16 Years
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 13
States / cities: Boulder, Colorado • Orlando, Florida • Tampa, Florida + 10 more

Conditions: Non-alcoholic Steatohepatitis, Hepatic Impairment
Interventions: Efinopegdutide; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Miami, Florida • Tampa, Florida • San Antonio, Texas

Conditions: Smoking &Amp; Tobacco Cessation
Interventions: Experimental Smoking Cessation Program, Control Smoking Cessation Program; Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1,647 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Long COVID, Post-Acute COVID-19 Syndrome
Interventions: Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling, Medications for symptoms management; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 20 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: TBI (Traumatic Brain Injury), Brain Concussion, Clinical Trial, Rehabilitation, Cognition, Psychosocial Functioning, Walking, Vision, Ocular, Mobile Application, Saliva, microRNA, Exercise
Interventions: Brain & Walk Exercise Every Day (BraW-Day); Behavioral
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 18 Years to 40 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Postural Tachycardia Syndrome
Interventions: Stellate ganglion block, Sham injection of saline, Ropivacaine, Normal saline; Procedure · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Stanford, California

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Diabetes Mellitus
Interventions: Aliskiren + Valsartan; Drug
Lead sponsor: HeartDrug Research LLC; Other
Eligibility: 21 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Celiac Disease
Interventions: Cohort 1 in Part A, Cohort 2 in Part A, Placebo: Group 1 in Part B and Part C, Group 2 in Part B and Part C, Group 3 in Part B and Part C, Group 4 in Part B and Part C; Drug · Other
Lead sponsor: Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 23
States / cities: Birmingham, Alabama • Anaheim, California • St. Petersburg, Florida + 20 more

Conditions: Multiple Sclerosis
Interventions: Low-fat diet; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Depression, Traumatic Brain Injury
Interventions: aerobic exercise, stretching and flexibility program; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 14 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Arthritis, Rheumatoid
Interventions: peficitinib, Placebo, methotrexate; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Huntington Beach, California • La Jolla, California + 16 more

Conditions: Hypertension
Interventions: iHealth Wireless Blood Pressure Monitor; Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Cognitive Impairment, no Dementia (CIND)
Interventions: Aerobic Exercise, DASH diet, Health education control; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 55 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cognition, Concentration, Attention, Focus
Interventions: Cognitive Nutritional Supplement, Placebo; Dietary Supplement · Other
Lead sponsor: Pharmavite LLC; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 422 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Parkinson's Disease, Parkinson Disease, Dyskinesias
Interventions: ropinirole controlled-release (REQUIP CR) for RLS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 69
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 61 more

Conditions: Alzheimer Disease
Interventions: Simufilam, Placebo; Drug
Lead sponsor: Cassava Sciences, Inc.; Industry
Eligibility: 50 Years to 87 Years
Enrollment: 804 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 74
States / cities: Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 65 more

Conditions: Body Image, Self Esteem
Interventions: Celebrandome; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 11 Years to 16 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Heart Failure and Reduced Ejection Fraction
Interventions: LCZ696 (sacubitril/valsartan), Enalapril, Placebo of Enalapril, Placebo of LCZ696; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 81
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 69 more

Conditions: Achilles Tendon Rupture, Blood Flow Restriction Therapy, Achilles Tendon Repairs/Reconstructions, Dynamic Blood Flow Restriction
Interventions: Blood Flow Restriction Resistance Training (BFR-RT), Sham Blood Flow Restriction, Standard Physical Therapy; Device · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Plasma Rich in Growth Factors in Corneal Endothelial Transplantation

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

School Partnered Collaborative Care (SPACE) Intervention for Children With Type 1 Diabetes

Use of Tranexamic Acid in Reduction of Post-Op Complications in Mohs Micrographic Surgery

Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

An Innovative Conversational Agent (Quitbot) for Smoking Cessation

A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid

Dual-Task Exercise for Mild Traumatic Brain Injury (mTBI)

Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

Low Fat Diet for Fatigue in MS

Exercise Training in Depressed Traumatic Brain Injury Survivors

A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate

Assessing Blood Pressure Remotely in Childhood Cancer Survivors

ENLIGHTEN: Exercise and NutritionaL Interventions for coGnitive and Cardiovascular HealTh ENhancement

A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

Celebrandome: Preliminary Study

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

Project Tendura: The Impact of Blood Flow Restriction Resistance Training (BFR-RT) in Patients With Achilles Tendon Rupture (ATR) Repair